产品
编 号：F512777
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 903512-50-5
产品详情
生物活性：
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research.
体外研究：
Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%.Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells.Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells.
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research.
体外研究：
Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%.Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells.Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备